PubRank

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Clinical Trial ID NCT01006980

PubWeight™ 130.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01006980

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 45.46
2 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 36.57
3 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
4 RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012 6.93
5 Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014 4.60
6 Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012 3.09
7 Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011 2.89
8 BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011 2.10
9 Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012 1.60
10 Targeting BRAF for patients with melanoma. Br J Cancer 2010 1.56
11 Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011 1.52
12 Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013 1.41
13 Beyond BRAF: where next for melanoma therapy? Br J Cancer 2014 1.26
14 B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013 1.14
15 Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 2015 1.11
16 RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it. J Clin Invest 2011 1.02
17 Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010 1.01
18 Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 2014 0.93
19 RASopathic skin eruptions during vemurafenib therapy. PLoS One 2013 0.91
20 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
21 Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res 2015 0.86
22 Targeting oncogenic BRAF in human cancer. Curr Top Microbiol Immunol 2012 0.86
23 Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget 2015 0.81
24 Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol 2014 0.81
25 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
26 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
27 MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A 2015 0.77
28 Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations. J Dermatol 2015 0.76
29 Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 2016 0.76
30 New horizons in melanoma treatment: targeting molecular pathways. Ochsner J 2010 0.76
31 Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clin Cancer Res 2015 0.76
32 FDA's Expedited Approval Mechanisms for New Drug Products. Biotechnol Law Rep 2015 0.75
Next 100